SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : QLT PhotoTherapeutics (QLTI)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Joe Stephenson who wrote (38)8/22/1996 10:45:00 PM
From: John Metcalf   of 1321
 
As Doug Meetmer noted, QLTIF is not alone in developing products for photodynamic therapy. In my view, if the concept acquires widespread recognition and use, all the companies in the niche will benefit. In addition to QLTIF and PCYC, PDTI must be considered. DUSA has also shown good clinical results (actinic keratoses), but must have a proprietary product to be considered with the others.

From the investor's perspective, it makes sense to invest in all three companies rather than one. If there is a stunning clinical success, or sudden approval (PCYC's Gadolite has been pending approval for 11 months), you would get the home run plus the other stocks you hold would rally in sympathy.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News